Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia
- PMID: 21851490
- DOI: 10.1111/j.1469-0691.2011.03629.x
Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia
Abstract
Pneumococcal surface proteins (PSPs) elicit antibody responses in infants and young children exposed to Streptococcus pneumoniae. These seroresponses could contribute to the aetiological diagnosis of pneumococcal disease, e.g. during the clinical development of novel PSP-based vaccines. In this study, we assessed the kinetics of antibody responses to three highly conserved and immunogenic PSPs (pneumococcal histidine triad D (PhtD), pneumococcal choline-binding protein A (PcpA), and serine proteinase precursor A (PrtA)) in 106 children (median age, 21.3 months; males, 58.5%) admitted for pneumococcal bacteraemia. Anti-PhtD, anti-PcpA and anti-PrtA antibodies were measured by ELISA, and compared in 61 pairs of acute (≤7 days) and convalescent (>14 days of admission) serum samples. Acute serum titres were similar to those observed in healthy children, and were unaffected by the acid dissociation of circulating immune complexes. Despite proven bacteraemia, seroresponses (≥2-fold increase in anti-PSP antibody concentrations) were only identified in 31 of 61 children (50.8%), directed against PrtA (n = 23, 37.7%), PcpA (n = 19, 31.1%), and PhtD (n = 16, 26.2%), or several PSPs (two PSPs, n = 13, 21.3%; three PSPs, n = 7, 11.5%). Certain seroresponses were very strong (maximal fold-increases: PhtD, 26; PcpA, 72; PrtA, 12). However, anti-PSP antibody concentrations failed to increase in the convalescent sera of 30 of 61 (49.2%) bacteraemic children, and even declined (≥2 fold) in 13 of 61 (21.3%), mostly infants aged <6 months (8/13, 61.5%), possibly through consumption of maternal antibodies. Thus, pneumococcal bacteraemia may fail to elicit antibody responses, and may even have an antibody-depleting effect in infants. This novel observation identifies an important limitation of serology-based studies for the identification of bacteraemic children.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.
Similar articles
-
Immunity to pneumococcal surface proteins in children with community-acquired pneumonia: a distinct pattern of responses to pneumococcal choline-binding protein A.Clin Microbiol Infect. 2011 Aug;17(8):1232-8. doi: 10.1111/j.1469-0691.2010.03389.x. Epub 2010 Dec 17. Clin Microbiol Infect. 2011. PMID: 21040158
-
Influence of age, social patterns and nasopharyngeal carriage on antibodies to three conserved pneumococcal surface proteins (PhtD, PcpA and PrtA) in healthy young children.Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):43-9. doi: 10.1007/s10096-012-1712-9. Epub 2012 Aug 18. Eur J Clin Microbiol Infect Dis. 2013. PMID: 22903166
-
Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.Hum Vaccin Immunother. 2015;11(2):489-97. doi: 10.4161/21645515.2014.990861. Hum Vaccin Immunother. 2015. PMID: 25692218 Free PMC article.
-
Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.Vaccine. 2012 Dec 14;30(52):7461-8. doi: 10.1016/j.vaccine.2012.10.076. Epub 2012 Nov 2. Vaccine. 2012. PMID: 23123106 Clinical Trial.
-
Limitation of the delta neutrophil index for assessing bacteraemia in immunocompromised children.Clin Chim Acta. 2014 Sep 25;436:319-22. doi: 10.1016/j.cca.2014.06.020. Epub 2014 Jun 27. Clin Chim Acta. 2014. PMID: 24978822 Review.
Cited by
-
Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults.PLoS One. 2013 Jul 23;8(7):e70365. doi: 10.1371/journal.pone.0070365. Print 2013. PLoS One. 2013. PMID: 23894641 Free PMC article.
-
Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.Clin Vaccine Immunol. 2014 Jan;21(1):56-65. doi: 10.1128/CVI.00430-13. Epub 2013 Oct 30. Clin Vaccine Immunol. 2014. PMID: 24173029 Free PMC article. Clinical Trial.
-
A Pneumococcal Protein Array as a Platform to Discover Serodiagnostic Antigens Against Infection.Mol Cell Proteomics. 2015 Oct;14(10):2591-608. doi: 10.1074/mcp.M115.049544. Epub 2015 Jul 16. Mol Cell Proteomics. 2015. PMID: 26183717 Free PMC article.
-
PrtA immunization fails to protect against pulmonary and invasive infection by Streptococcus pneumoniae.Respir Res. 2018 Sep 25;19(1):187. doi: 10.1186/s12931-018-0895-8. Respir Res. 2018. PMID: 30253765 Free PMC article.
-
Prevalence and clonal distribution of pcpA, psrP and Pilus-1 among pediatric isolates of Streptococcus pneumoniae.PLoS One. 2012;7(7):e41587. doi: 10.1371/journal.pone.0041587. Epub 2012 Jul 25. PLoS One. 2012. PMID: 22848535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous